SEC Tracker
Get the app

Replimune Group REPL

Patel Sushil (Chief Strategy Officer) plans to sell 15,000 REPL shares, about $188,550

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Dec 16, 2024
  2. Broker: J.P. Morgan Securities LLC
  3. Shares acquired by: Rsetricted Stock Units
  4. 10b5-1 plan adopted: Apr 3, 2024

All of Patel Sushil's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 10,000 shares at $12.42 on Dec 16, 2024 · Form 4

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Replimune Group files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  2. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  3. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  4. Annexon ANNX public float $244M, Jun 30, 2025
  5. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025